Klinikum rechts der Isar München der TU München

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma	Esophagogastric Adenocarcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-04-21		NCT06731803
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric adenocarcinoma, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorder	Recruiting	Phase 1	2025-12-19		NCT07059299

Clinical trials